Table S3. Additional cross-tumor* validation of the six race-differentiated SCNAS in TCGA.

| Cytoband†  | Chromosome position† | Breast and prostate SCNA type | Cancer Type* | Chromosome position† | Length (Mb) | SCNA type | Beta coefficient† | SE | T-statistic | P-value |
|------------|----------------------|-------------------------------|--------------|----------------------|-------------|-----------|------------------|----|-------------|---------|
| 5q11.2-q14.15:51204966-80506380 | Del | Endometrial | 5:50124837-63329958 | 13.21 | Del | -0.023 | 0.022 | -1.03 | 0.301 |
| 5:50124837-63329958 | Del | Endometrial | 5:53299959-94282979 | 30.95 | Del | -0.016 | 0.021 | -0.80 | 0.426 |
| Ovarian | 5:45378457-55750914 | Del | 0.088 | 0.037 | 3.73 | 0.018 |
| Ovarian | 5:55750915-59044767 | Del | 0.185 | 0.082 | 2.27 | 0.024 |
| Ovarian | 5:59044768-62065114 | Del | 0.175 | 0.071 | 2.48 | 0.014 |
| Lung | 5:62065115-125175058 | Del | 0.064 | 0.056 | 1.13 | 0.258 |
| Kidney | NA | NA | NA | NA | NA | NA | NA |
| 5q11.2-q14.15:94139355-102688824 | Del | Endometrial | 5:63329959-94282979 | 30.95 | Del | -0.016 | 0.021 | -0.80 | 0.426 |
| Ovarian | 5:62065115-125175058 | Del | 0.064 | 0.056 | 1.13 | 0.258 |
| Lung | 5:64444923-136407584 | Del | -0.016 | 0.034 | -0.47 | 0.641 |
| Kidney | NA | NA | NA | NA | NA | NA | NA |
| 8q21.11-q21.8:78097650-84211555 | Amp | Endometrial | NA | NA | NA | NA | NA | NA |
| Ovarian | 8:65946564-115168901 | Amp | -0.144 | 0.061 | -2.38 | 0.018 |
| Lung | 8:64945035-93539198 | Amp | -0.027 | 0.041 | -0.66 | 0.507 |
| Kidney | NA | NA | NA | NA | NA | NA | NA |
| 8q21.3-q24.3:8:90059223-144568457 | Amp | Endometrial | 8:95579787-99567648 | 3.99 | Amp | 0.045 | 0.030 | 1.50 | 0.135 |
| 8:95579787-99567648 | Amp | 0.76 | 0.055 | 0.030 | 1.87 | 0.063 |
| 8:100907360-140610028° | 39.70 | Amp | 0.070 | 0.028 | 2.49 | 0.013 |
| 8:140610029-143946427° | 3.34 | Amp | 0.052 | 0.030 | 1.74 | 0.082 |
| Ovarian | 8:65946564-115168901 | Amp | -0.144 | 0.061 | -2.38 | 0.018 |
| Lung | 8:93539199-143507187 | Amp | -0.045 | 0.040 | -1.12 | 0.262 |
| Kidney | 8:130667622-130732818 | Amp | -0.001 | 0.027 | -0.02 | 0.983 |
| 11q22.3 | Del | Endometrial | 11:83797177-1209311054 | 37.14 | Del | -0.025 | 0.019 | -1.32 | 0.189 |
| Ovarian | NA | NA | NA | NA | NA | NA | NA |
| Lung | 11:104239997-113587551 | Del | -0.012 | 0.031 | -0.40 | 0.692 |
| Kidney | NA | NA | NA | NA | NA | NA | NA |
|                |   Del       |   3.93 |   Del |    11.17 |   Del |   9.33 |   Del |   5.17 |   Del |   65.78 |   Del |
|----------------|------------|--------|------|----------|------|--------|------|--------|------|---------|------|
| **13q12.3-q21**| **13:3194050-59628349** | **13:46090462-50019374** | **13:50019375-61187197** | **13:31158332-40490760** | **13:40490761-40716260** | **13:40716261-51631042** | **13:51631043-56802296** | **13:19650694-85435149** |
|                | 13q12.3-q21.13:3194050-59628349 | Del | 14.70 | Del | 0.039 | 0.023 | -1.68 | 0.094 |
|                | 13:46090462-50019374 | Del | 3.93 | Del | -0.028 | 0.025 | -1.12 | 0.261 |
|                | 13:50019375-61187197 | Del | 11.17 | Del | -0.031 | 0.024 | -1.31 | 0.192 |
|                | 13:31158332-40490760 | Del | 9.33 | Del | -0.169 | 0.067 | -2.52 | 0.012 |
|                | 13:40490761-40716260 | Del | 0.23 | Del | -0.113 | 0.071 | -1.59 | 0.113 |
|                | 13:40716261-51631042 | Del | 10.91 | Del | -0.138 | 0.068 | -2.03 | 0.043 |
|                | 13:51631043-56802296 | Del | 5.17 | Del | -0.097 | 0.070 | -1.39 | 0.164 |
|                | 13:19650694-85435149 | Del | 65.78 | Del | 0.020 | 0.031 | 0.64 | 0.522 |

**Abbreviations** - AA=African American; Amp=Amplification; Del=Deletion; EA=European American; NA=no recurrent SCNAs were identified by GISTIC2; SE=Standard error of the coefficient.

* The following four tumor types were evaluated along with their sample sizes - Endometrial (N: AA=102, EA=360); Ovarian (N: AA=31, EA=453); Lung (N: AA=80, EA=735); Kidney (N: AA=118, EA=711).

† positive beta coefficient signifies greater DNA Amplification in AA relative to EA.

‡ negative beta coefficient signifies greater DNA Deletion in AA relative to EA.

§ Based on human genome build hg19

¶ SCNAs where significant race difference coefficients were consistent in direction with the breast and prostate cancer results (i.e., more extreme gain and loss in AA compared to EA).